In imatinib-sensitive and imatinib-resistant BCR-ABL-positive CML cells, synergistic apoptotic cell death is triggered upon MAKV-8-imatinib co-treatment. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.